Assessment of SSD in Outpatients Using SSS-CN

CompletedOBSERVATIONAL
Enrollment

1,863

Participants

Timeline

Start Date

September 1, 2017

Primary Completion Date

December 30, 2021

Study Completion Date

December 30, 2021

Conditions
Somatization Disorder
Interventions
DRUG

Deanxit, SSRI or SRNI

After recruiting participants and collecting the baseline data, the SSS-CN, PHQ-15, PHQ-9 and GAD-7 questionnaires will be carried out. An independent diagnosis will be made by primary care physician using the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criterion standard. Deanxit, selective serotonin reuptake inhibitors (SSRI) or serotonin-norepinephrine reuptake inhibitors (SNRI) will be selectively prescribed according to the severity category assessed by physician. Two, 6,10 weeks after patients with correspondent medications, a face-to-face interview, telephone interview or mobile-apps survey will be underwent to follow-up using the SSS-CN, PHQ-15, PHQ-9 and GAD-7 checklists.

Trial Locations (1)

200127

Renji Hospital, Shanghai

All Listed Sponsors
lead

RenJi Hospital

OTHER

NCT03513185 - Assessment of SSD in Outpatients Using SSS-CN | Biotech Hunter | Biotech Hunter